Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 13/20 | 0.58 |
| ▸ | ABL1 | P00519 | 5/20 | 0.58 |
| ▸ | ABL2 | P42684 | 5/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | PRKCA | P17252 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.39 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.39 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.39 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8586040 | 0.83 | EGFR (0.55) | EGFRABL1ABL2PRKCANPC1 | |
| SCHEMBL2461575 | 0.81 | EGFR (0.69) | EGFRABL1ABL2MEN1KMT2A | |
| SCHEMBL27627681 | 0.80 | EGFR (0.91) | EGFRABL1ABL2KDRPRKCA | |
| SCHEMBL29795688 | 0.80 | EGFR (0.91) | EGFRABL1ABL2KDRPRKCA | |
| SCHEMBL2463632 | 0.74 | EGFR (1.00) | EGFRABL1ABL2KDRPRKCA | |
| SCHEMBL29406611 | 0.74 | EGFR (1.00) | EGFRABL1ABL2KDRPRKCA | |
| SCHEMBL16964814 | 0.67 | EGFR (0.40) | EGFRABL1ABL2MEN1KMT2A | |
| SCHEMBL7494877 | 0.65 | EGFR (0.72) | EGFRABL1ABL2PRKCA | |
| SCHEMBL7491933 | 0.65 | EGFR (0.72) | EGFRABL1ABL2PRKCA | |
| SCHEMBL7494688 | 0.65 | EGFR (0.72) | EGFRABL1ABL2PRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132164-A1 | PNU ANTHRACYCLINE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4076459-B1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2026-04-29 | — | — | EP | disclosed |
| US-12595248-B2 | PRMT5 inhibitors | MERCK SHARP & DOHME LLC (US) | 2026-04-07 | — | — | US | disclosed |
| US-12595262-B2 | PRMT5 inhibitors | MERCK SHARP & DOHME LLC (US) | 2026-04-07 | — | — | US | disclosed |
| US-12583871-B2 | PRMT5 inhibitors | MERCK SHARP & DOHME LLC (US) | 2026-03-24 | — | — | US | disclosed |
| US-12552826-B2 | PRMT5 inhibitors | MERCK SHARP & DOHME LLC (US) | 2026-02-17 | — | — | US | disclosed |
| EP-4076460-B1 | 1,4-DIHYDRO-2H-SPIRO[ISOQUINOLINE-3,4'-PIPERIDINE DERIVATIVES AS PRMT5 INHIBITORS FOR THE TREATMENT OF CANCER | MERCK SHARP & DOHME LLC (US) | 2026-01-21 | — | — | EP | disclosed |
| US-12516321-B2 | RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA) | SIRNA THERAPEUTICS, INC. (US) | 2026-01-06 | — | — | US | disclosed |
| US-20260000691-A1 | COMPOUNDS, METHODS, AND TREATMENTS FOR ABNORMAL SIGNALING PATHWAYS FOR PRENATAL AND POSTNATAL DEVELOPMENT | JENNINGS BARBARA BROOKE (US) | 2026-01-01 | — | — | US | disclosed |
| US-12486503-B2 | Short interfering nucleic acid (siNA) compositions | SIRNA THERAPEUTICS, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| US-8034815-B2 | Imidazol-1-yl-(4-pyridin-2-yl-piperazin-1-yl)-methanethione; Critical Outcome Technologies' Iead compound (COTI); kinase inhibitor; anticarcinogenic agent; especially small cell lung cancer; cervical, ovarian, skin, prostate, breast, colorectal, head, neck, or kidney cancer, sarcoma, leukemia | CRITICAL OUTCOME TECHNOLOGIES, INC. (CA) | 2011-10-11 | — | — | US | disclosed |
| EP-2318406-A1 | THIOSEMICARBAZONE INHIBITOR COMPOUNDS AND CANCER TREATMENT METHODS | Critical Outcome Technologies, Inc. (CA) | 2011-05-11 | — | — | EP | disclosed |
| WO-2011049722-A1 | PYRAZOLO [3,4-b] PYRIDIN-4-ONE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-04-28 | — | — | WO | disclosed |
| WO-2011022805-A1 | NOVEL COLCHICINE DERIVATIVES, METHODS AND USES THEREOF | ALBERTA HEALTH SERVICES (CA) | 2011-03-03 | — | — | WO | disclosed |
| WO-2010006438-A1 | THIOSEMICARBAZONE INHIBITOR COMPOUNDS AND CANCER TREATMENT METHODS | CRITICAL OUTCOME TECHNOLOGIES INC. (CA) | 2010-01-21 | — | — | WO | disclosed |
| US-20100015140-A1 | Inhibitor Compounds and Cancer Treatment Methods | CRITICAL OUTCOME TECHNOLOGIES INC. (CA) | 2010-01-21 | — | — | US | disclosed |
| EP-2121681-A1 | COMPOUNDS AND METHOD FOR TREATMENT OF CANCER | Critical Outcome Technologies, Inc. (CA) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008083491-A1 | COMPOUNDS AND METHOD FOR TREATMENT OF CANCER | CRITICAL OUTCOME TECHNOLOGIES INC. (CA) | 2008-07-17 | — | — | WO | disclosed |
| US-20080171744-A1 | COMPOUNDS AND METHOD FOR TREATMENT OF CANCER | 6441513 CANADA INC. (CA) | 2008-07-17 | — | — | US | disclosed |
| WO-1998043973-A1 | INTERMEDIATE PRODUCTS AND METHOD FOR THE PRODUCTION OF PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 1998-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12595248-B2 | PRMT5 inhibitors | PRMT5, PRMT1, PRMT6 | EGFR 3903/4885ABL1 651/4885ABL2 2085/4885 |
| US-20260000691-A1 | COMPOUNDS, METHODS, AND TREATMENTS FOR ABNORMAL SIGNALING PATHWAYS FOR PRENATAL AND POSTNATAL DEVELOPMENT | PDK1, IP6K1, IP6K3 | EGFR 3208/4885ABL1 4410/4885ABL2 4350/4885 |
| US-20080171744-A1 | COMPOUNDS AND METHOD FOR TREATMENT OF CANCER | SLC6A6, SLCO1B3, SLC5A1 | EGFR 1170/4885ABL1 1293/4885ABL2 3158/4885 |
| US-20100015140-A1 | Inhibitor Compounds and Cancer Treatment Methods | MTOR, RICTOR, RPTOR | EGFR 13/4885ABL1 484/4885ABL2 560/4885 |
| US-12595262-B2 | PRMT5 inhibitors | PRMT1, PRMT5, CARM1 | EGFR 2928/4885ABL1 326/4885ABL2 887/4885 |
| US-20260132164-A1 | PNU ANTHRACYCLINE DERIVATIVES AND METHODS OF USE THEREOF | TOP1, NCL, NOLC1 | EGFR 230/4885ABL1 146/4885ABL2 2251/4885 |
| US-12583871-B2 | PRMT5 inhibitors | PRMT5, PRMT1, PRMT3 | EGFR 4481/4885ABL1 455/4885ABL2 2353/4885 |
| US-12552826-B2 | PRMT5 inhibitors | PRMT5, PRMT6, PRMT1 | EGFR 2925/4885ABL1 503/4885ABL2 1999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.